| Citation: |
LU Chang, SHEN Shujing, MAO Yuhuan, JI Yingying, LI Peipei, CAO Hui, WANG Ye, LI Xingya. Correlation of Tumor Markers with Clinical Efficacy of Advanced Lung Adenocarcinoma Patients with EGFR Mutation[J]. Cancer Research on Prevention and Treatment, 2017, 44(7): 485-488. DOI: 10.3971/j.issn.1000-8578.2017.16.1530
|
To explore the correlation of serum tumor markers expression with the mutation rate and efficacy of the patients with EGFR-positive advanced lung adenocarcinoma.
We selected 143 patients who were molecular pathologically diagnosed as positive EGFR mutation had received epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) treatment. According to CYFRA21-1, CEA and NSE expression levels before treatment, the patients were randomly divided into high level group and normal level group, respectively. We retrospectively analyzed progression-free survival(PFS) after the targeted therapy to explore the relationship between tumor markers expression before treatment and the efficacy of EGFR-TKIs as the first-line treatment on non-small cell lung cancer patients.
The efficacy of high CEA group was significantly better than that of normal CEA group(P < 0.05). The curative effect of normal CYFRA21-1 group was longer than that of high CYFRA21-1 group(P < 0.05). The median PFS had no significant difference between high NSE group and normal NSE group(P > 0.05). In subgroup analysis, ECOG PS < 2 group was better than PS≥2 group in PFS(P < 0.05). Non-smoking history group was better than smoking history group in curative effect(P < 0.05). Gender, age, TNM stage, mutation type and targeted drug had no significant differences in statistics. Multivariate survival analysis showed that median PFS was not related with ECOG PS score, smoking history or the state of CYFRA21-1, and the high expression of CEA was an independent prognostic factor for EGFR-TKIs as the first-line treatment.
High CEA has a certain correlation with EGFR mutation status. It is a positive independent prognostic factor for the evaluation of targeted therapy.
| [1] |
Jemal A, Siegel R, Ward E. Cancer statistics, 2008[J]. CA Cancer J Clin, 2008, 58(2): 71-96. doi: 10.3322/CA.2007.0010
|
| [2] |
薛洪省, 周少华, 卢万鹏, 等.非小细胞肺癌靶向治疗的靶点研究进展[J].中国肺癌杂志, 2013, 16(2): 107-13. doi: 10.3779/j.issn.1009-3419.2013.02.09
Xue HS, Zhou SH, Lu WP, et al. The targets research of non-small cell lung cancer targeted therapy[J]. Zhongguo Fei Ai Za Zhi, 2013, 16(2): 107-13. doi: 10.3779/j.issn.1009-3419.2013.02.09
|
| [3] |
Ettinger DS, Wood DE, Akerley W, et al. NCCN guidelines insights: non-small cell lung cancer, Version 4. 2016[J]. J Natl Compr Canc Netw, 2016, 14(3): 255-64. doi: 10.6004/jnccn.2016.0031
|
| [4] |
Dong Y, Zheng X, Yang Z, et al. Serum carcinoembryonic antigen, neuron-specific enolase as biomarkers for diagnosis of non-small cell lung cancer[J]. J Cancer Res Ther, 2016, 12(supplement): 34-6. http://www.medscape.com/medline/abstract/27721249
|
| [5] |
Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer[J]. Lung cancer, 2012, 76(2): 138-43. doi: 10.1016/j.lungcan.2011.11.012
|
| [6] |
Cedrés S, Nuñez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer(NSCLC)[J]. Clin Lung Cancer, 2011, 12(3): 172-9. doi: 10.1016/j.cllc.2011.03.019
|
| [7] |
张艳, 刘晶, 杨梦迪.非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义[J].临床药物治疗杂志, 2014, 12(5): 35-9. http://www.cnki.com.cn/Article/CJFDTOTAL-MDJB201605069.htm
Zhang Y, Liu J, Yang MD. Clinical significance of serum tumor markers in predicting outcomes of targeted therapy in advanced non-small cell lung cancer[J]. Lin Chuang Yao Wu Zhi Liao Za Zhi, 2014, 12(5): 35-9. http://www.cnki.com.cn/Article/CJFDTOTAL-MDJB201605069.htm
|
| [8] |
Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumor marker in non-small cell lung cancer(NSCLC)[J]. Lung Cancer, 2003, 41(3): 311-20. doi: 10.1016/S0169-5002(03)00232-0
|
| [9] |
Sharma SK, Bhat S, Chandel V, et al. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer[J]. J Carcinoq, 2015, 14: 7. doi: 10.4103/1477-3163.170662
|
| [10] |
Tanaka K, Hata A, Kaji R, et al. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation[J]. J Thorac Oncol, 2013, 8(7): 892-8. doi: 10.1097/JTO.0b013e31828c3929
|
| [11] |
杜军华, 乔洪源, 尹宜发.血清CEA、CA125及Cyfra21-1水平对中晚期非小细胞肺癌患者预后的影响[J].肿瘤防治研究, 2016, 43(2): 137-40. doi: 10.3971/j.issn.1000-8578.2016.02.009
Du JH, Qiao HY, Yin YF. Prognostic value of serum CEA, CA125 and Cyfra21-1 in patients with advanced non-small cell lung cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2016, 43(2): 137-40. doi: 10.3971/j.issn.1000-8578.2016.02.009
|
| [12] |
陈燕, 彭伟, 黄艳芳, 等.治疗前血清神经元特异性烯醇化酶水平在预测晚期非小细胞肺癌脑转移及预后中的意义[J].中国肺癌杂志, 2015, 37(7): 508-11. http://cdmd.cnki.com.cn/Article/CDMD-10459-1014392841.htm
Chen Y, Peng W, Huang YF, et al. Significance of serum neuron-secific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer[J]. Zhongguo Fei Ai Za Zhi, 2015, 37(7): 508-11. http://cdmd.cnki.com.cn/Article/CDMD-10459-1014392841.htm
|
| [13] |
Shoji F, Yonshino I, Yano T, et al. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung ademocarcinomas[J]. Cancer, 2007, 110(12): 2793-8. doi: 10.1002/cncr.v110:12
|
| [14] |
Jung M, Kim SH, Hong S, et al. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib[J]. Yonsei Med J, 2012, 53(5): 931-9. doi: 10.3349/ymj.2012.53.5.931
|
| [15] |
Qin HF, Qu LL, Liu H, et al. Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer[J]. Asian Pac J Cancer Prev, 2013, 14(7): 4205-8. doi: 10.7314/APJCP.2013.14.7.4205
|
| [16] |
Cui S, Xiong L, Lou Y, et al. Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors[J]. J Thorac Dis, 2016, 8(1): 68-78. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740173/
|
| [17] |
谢亚琳, 梁继珍, 苏宁.吉非替尼与厄洛替尼在EGFR基因敏感突变晚期NSCLC患者一线治疗中的疗效比较[J].南方医科大学学报, 2015, 35(3): 446-9. http://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201503028.htm
Xie YL, Liang JZ, Su N. Gefitinib versus Erlotinib as fist-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer[J]. Nanfang Yi Ke Da Xue Xue Bao, 2015, 35(3): 446-9. http://www.cnki.com.cn/Article/CJFDTOTAL-DYJD201503028.htm
|
| [18] |
Okamoto T, Nakamura T, Ikeda J, et al. Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer[J]. Eur J Cancer, 2005, 41(9): 1286-90. doi: 10.1016/j.ejca.2005.03.011
|
| [19] |
Liu M, Zhou C, Zheng J. Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition[J]. Am J Transl Res, 2015, 7(10): 2026-35. https://www.researchgate.net/publication/286293726_Cigarette_smoking_impairs_the_response_of_EGFR-TKIs_therapy_in_lung_adenocarcinoma_patients_by_promoting_EGFR_signaling_and_epithelial-mesenchymal_transition
|
| [20] |
Eigenmann MJ, Frances N, Hoffmann G, et al. Combining nonclinical experiments with translational PKPD modeling to differentiate erlotinib and gefitinib[J]. Mol Cancer Ther, 2016, 15(12): 3110-9. doi: 10.1158/1535-7163.MCT-16-0076
|
| [21] |
柳菁菁, 张爽, 吴春娇, 等.中国不同表皮生长因子受体敏感突变类型非小细胞肺癌患者接受表皮生长因子受体酪氨酸激酶抑制剂一线治疗的临床疗效比较[J].中华肿瘤杂志, 2016, 38(3): 211-7. http://cdmd.cnki.com.cn/Article/CDMD-10246-1015428797.htm
Liu JJ, Zhang S, Wu CJ, et al. Comparison of clinical outcoms of patients with non-small cell cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment[J]. Zhonghua Zhong Liu Za Zhi, 2016, 38(3): 211-7. http://cdmd.cnki.com.cn/Article/CDMD-10246-1015428797.htm
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: